Earnings Summary

Voyager Therapeutics, Inc.’s revenue jumped 319.2% since last year same period to $90.06Mn in the Q4 2023. On a quarterly growth basis, Voyager Therapeutics, Inc. has generated 1851.91% jump in its revenue since last 3-months.

Voyager Therapeutics, Inc.’s net profit jumped 338.7% since last year same period to $56.4Mn in the Q4 2023. On a quarterly growth basis, Voyager Therapeutics, Inc. has generated 317.73% jump in its net profits since last 3-months.

Voyager Therapeutics, Inc.’s net profit margin jumped 8.9% since last year same period to 62.62% in the Q4 2023. On a quarterly growth basis, Voyager Therapeutics, Inc. has generated 111.15% jump in its net profit margins since last 3-months.

Voyager Therapeutics, Inc.’s price-to-earnings ratio after this Q4 2023 earnings stands at 2.77.

Voyager Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.44 - a -51.72% fall from last quarter’s estimates.

Voyager Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.44.

Voyager Therapeutics, Inc.’s earning per share (EPS) jumped 304.92% since last year same period to 1.25 in the Q4 2023. This indicates that the Voyager Therapeutics, Inc. has generated 304.92% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Voyager Therapeutics, Inc.’s return on assets (ROA) stands at 0.3.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Voyager Therapeutics, Inc.’s return on equity (ROE) stands at 0.9.